TY - JOUR
T1 - Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma
AU - Trojan, Andreas
AU - Tinguely, Marianne
AU - Vallet, Sonia
AU - Seifert, Burkhardt
AU - Jenni, Bettina
AU - Zippelius, Alfred
AU - Witzens-Harig, Mathias
AU - Mechtersheimer, Gunhild
AU - Ho, Anthony D.
AU - Goldschmidt, Hartmut
AU - Jäger, Dirk
AU - Boccadoro, Mario
AU - Ladetto, Marco
PY - 2006/6/24
Y1 - 2006/6/24
N2 - Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.
AB - Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.
KW - Cyclooxygenase-2 (COX-2)
KW - Immunohistochemistry
KW - Multiple myeloma
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=33745769736&partnerID=8YFLogxK
M3 - Journal article
C2 - 16847764
AN - SCOPUS:33745769736
SN - 1424-7860
VL - 136
SP - 400
EP - 403
JO - Swiss Medical Weekly
JF - Swiss Medical Weekly
IS - 25-26
ER -